To assess the prognostic performance of an early global LUS score with respect to the mortality in ICU and duration of ventilation.
This is an international multicenter cohort study on data collected between March and April
2020. The first available lung ultrasound examination that used a 12-regions approach was
used to calculate the global LUS score.
Patients are included if they fulfilled the following criteria: 1) admitted to one of the
participating ICU; 2) for invasive ventilation; 3) for respiratory failure due to confirmed
COVID-19; and 4) having had a LUS examination performed within the first week of start of
invasive ventilation.
The primary and secondary outcomes were liberation from invasive ventilation and mortality.
Demographic, clinical and outcome variables will be presented as percentages for categorical
variables and as medians with interquartile ranges (IQR) for continuous variables.
Receiver operating characteristics (ROC) analysis will be used to derive the prognostic
discriminatory performance of global LUS score in determining succesful extubation and
mortality at day 28. The Youden index will be used to derive the optimal cut-off. The
association of global LUS with unfavourable outcomes are analyzed with Cox proportional
hazard analysis (for successful extubation and alive at day 28), logistic regression models
(mortality at day 28). Hazard ratio or odds ratio with 95% confidence intervals were
calculated for each outcome.
Inclusion Criteria:
- Admitted to an ICU participating in this study between February 1, 2020 and April 30,
2020
- Confirmed with reverse transcriptase polymerase chain reaction (RT-PCR) COVID-19
infection
- Having had received invasive ventilation
- Having had examined at least once with lung ultrasound under invasive ventilation
Exclusion Criteria:
- Age <18 years
- First examination with LUS in patients already under extracorporeal membrane
oxygenation (ECMO) support.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amsterdam, Netherlands
Investigator: Marcus J Schultz, MD PhD
marcus.j.schultz@gmail.com
Charalampos Pierrakos, MD
+3224772111
charalampos.pierrakos@chu-brugmann.be
Luigi Pisani, MD
luigipisani@gmail.com
Marcus J Schultz, MD, Principal Investigator
Amsterdam University Medical Centers, location 'AMC'